AKTX
AKARI Therapeutics
Company identity has not yet been verified
See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.
6Trials in this database
0Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)NCT02591862 | AKARI Therapeutics | Phase 2 | Completed | 2018-03-20Actual |
| Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 PolymorphismsNCT03427060 | AKARI Therapeutics | Phase 2 | Completed | 2018-11-15Actual |
| Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576NCT03588026 | AKARI Therapeutics | Phase 3 | Completed | 2020-09-03Actual |
| rVA576 (Coversin) Long Term Safety and Efficacy Surveillance StudyNCT03829449 | AKARI Therapeutics | Phase 3 | Terminated | 2020-08-29Actual |
| rVA576 in Adult Mild to Moderate Bullous Pemphigoid SubjectsNCT04035733 | AKARI Therapeutics | Phase 2 | Completed | 2020-03-12Actual |
| Nomacopan (rVA576) in Transplant Associated Thrombotic MicroangiopathyNCT04784455 | AKARI Therapeutics | Phase 3 | Terminated | 2024-05-15Actual |
Latest recorded trial changes
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.